Pharma Capital

Phase III Iclaprim trial results 'bode very well' for Motif Bio, says Northland Capital's Alexandre

Vadim Alexandre, head of research at Northland Capital Partners gives his view on Motif Bio Plc's (LON: MTFB, NASDAQ:MTFB) successful completion of a phase III clinical trial of its next-generation antibiotic, iclaprim.

The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections (ABSSSI).

''We know [Iclaprim] kills bacteria in the petri dish, we now know from this trial that it works in humans and we also know from a previous phase III trial ...  that it met its primary endpoint as well'', Alexandre says.

''There's very good reason to believe that the drug works and there's nothing in these results that are red flags to say that it shouldn't work in the second trial''.

 

View full MTFB profile

Motif Bio Plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.